Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Decerce

Neurology Starke, FL Medical Doctor

NPI 1497724421 CMS profile 112815

107 Edwards Rd, Suite F, Starke, FL 32091

Open in the dashboard

General payments

$2,291

117 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Decerce of Starke, FL is reported in the CMS Open Payments database as having received $2,291 across 117 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $273 8
2024 General $134 8
2023 General $184 11
2022 General $610 31
2021 General $612 30
2020 General $216 10
2019 General $264 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Decerce
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to John Decerce were reported at $273. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year John Decerce Neurology median Middle half National median
2019 $264 $474 $118–$2,177 $163
2020 $216 $367 $82–$2,309 $114
2021 $612 $438 $104–$2,547 $132
2022 $610 $442 $103–$2,388 $149
2023 $184 $464 $119–$2,312 $160
2024 $134 $468 $119–$2,323 $164
2025 $273 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. SK Life Science, Inc. $502 17 payments
  2. AbbVie, Inc. $266 14 payments
  3. Eisai Inc. $243 15 payments
  4. Jazz Pharmaceuticals Inc. $220 5 payments
  5. Upsher-Smith Laboratories LLC $193 10 payments
  6. Lilly USA, LLC $140 10 payments
  7. UCB, Inc. $128 8 payments
  8. Pfizer Inc. $126 7 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $126 8 payments
  10. Supernus Pharmaceuticals, Inc. $98 7 payments
  11. Other $249 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,141 116 payments
  2. Consulting Fee $150 1 payment
Products named General payments · program years 2019–2025
  1. Fycompa $231 14 payments
  2. QULIPTA $222 12 payments
  3. XCOPRI $210 2 payments
  4. NURTEC ODT $169 11 payments
  5. XYREM $150 1 payment
  6. XYWAV $150 1 payment
  7. TOSYMRA $131 8 payments
  8. ZEMBRACE SYMTOUCH $131 8 payments
  9. Briviact $113 7 payments
  10. QUDEXY $112 7 payments
  11. Other $897 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

778

Median for Neurology: 833

Drug cost

$105,415

Median for Neurology: $202,670

Branded share of claims

20.4%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ubrelvy Ubrogepant Brand 25 $40,485
Qulipta Atogepant Brand 24 $28,202
Xcopri Cenobamate Brand 12 $19,145
Lacosamide Generic 14 $5,872
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 16 $2,174
Buprenorphine Hcl Generic 22 $1,423
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 52 $1,255
Oxycodone Hcl Generic 69 $1,073
Teriflunomide Generic 11 $988
Gabapentin Generic 49 $539

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$13,450

Medicare's payments for the services billed

Medicare patients

31

Average age 64

Services billed

182

17 women, 14 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Diabetes 39%
Arthritis 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
  • PFIZER INC. $33
$33 — —
ZAVZPRET
  • PFIZER INC. $33
$33 — —
Epidiolex
  • JAZZ PHARMACEUTICALS INC. $18
$18 — —
UBRELVY
  • AbbVie, Inc. $8
$8 25 —
QULIPTA
  • AbbVie, Inc. $8
$8 24 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

117 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record